ACL National Chronic Disease Self-Management Education Resource Center
- Response deadline
- Jul 22, 2026 Closed
- Date posted
- Jun 22, 2026
- Source
- Open notice
Description
The purpose of this Notice of Funding Opportunity is to support one organization through a cooperative agreement to serve as the National Chronic Disease Self-Management Education (CDSME) Resource Center. This center will act as a central connector to the aging network for the discretionary and formula funded CDSME grants. It will offer individualized and tiered technical assistance, high-quality education, and a wide range of resources to increase the number of older adults and adults with disabilities who participate in evidence based CDSME and Self-Management Support Programs. The Resource Center will help the network provide cost-effective services that align with the purposes of the Older Americans Act, Title III-D. They will promote the advancement of the CDSME network through building partnerships, supporting data collection, reporting metrics, highlighting key achievements, and engaging stakeholders to encourage long-term sustainability of the programs.
Classifications
- NAICS93.734
Documents (1)
- Downloadhhs-2026-acl-aoa-cssg-0028-rev4_62626.pdfapplication/pdf384 KB
Contacts
Similar contracts
- Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research (R01 Clinical Trial Optional)Due Mar 5, 2029
- NIA Expanding Research in AD/ADRD (ERA) Summer Research Education Program (R25 Independent Clinical Trial Not Allowed)Due May 26, 2027
- Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)Due Jan 10, 2028
- Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)Due Feb 8, 2028
- NARMS Cooperative Agreement Program to Strengthen Antibiotic Resistance Surveillance in Retail Food SpecimensDue Apr 1, 2027
- Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)Due Jul 14, 2026